InsidersTradesSigma
Track the MARIMED INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, MARIMED INC. has recorded 152 insider filings. Market capitalisation: €33m. The latest transaction was filed on 1 September 2026 (Levée d'options). Among the most active insiders: Shaw Timothy. Every trade is free.
152
Insider Decl.
n/a
Thresholds
€4,147
1 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,416 of 29,064 companies
32.9
score / 100
Value45
Quality21
FCF yld18%
Earn yld-44%
EV/EBITDA14.5x
ROE-24%
Gross mgn36%
Net mgn-9.1%
Debt/EBITDA10.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 September 2026
Declarations152 total
65,000 shares0Common stockSEC:0001522767-26-000170:0
22,523 shares@ US$0.08160.0056% mcap23.3% of flowCommon stockSEC:0001522767-26-000170:1
14,781 shares@ CA$0.06620.0026% mcap46.3% of flowCommon SharesTSXSEDI:4754079
42,656 sharesCommon SharesTSXSEDI:4754078
42,656 sharesRestricted Share UnitsTSXSEDI:4754077
173,077 sharesCommon SharesTSXSEDI:4754076
173,077 sharesRestricted Share UnitsTSXSEDI:4754075
173,077 sharesRestricted Share UnitsTSXSEDI:4754074
30,589 shares@ CA$0.06620.0055% mcap100.0% of flowCommon SharesTSXSEDI:4754073
88,276 sharesCommon SharesTSXSEDI:4754072
38,281 sharesRestricted Share UnitsTSXSEDI:4754071
49,995 sharesRestricted Share UnitsTSXSEDI:4754070
10,612 shares@ CA$0.06620.0019% mcap10.8% of flowCommon SharesTSXSEDI:4754068
30,625 sharesCommon SharesTSXSEDI:4754067
30,625 sharesRestricted Share UnitsTSXSEDI:4754066
192,308 sharesCommon SharesTSXSEDI:4754065
192,308 sharesRestricted Share UnitsTSXSEDI:4754064
192,308 sharesRestricted Share UnitsTSXSEDI:4754063
11,370 shares@ CA$0.06620.0020% mcap8.2% of flowCommon SharesTSXSEDI:4754062
32,813 sharesCommon SharesTSXSEDI:4754061
32,813 sharesRestricted Share UnitsTSXSEDI:4754060
192,308 sharesCommon SharesTSXSEDI:4754059
192,308 sharesRestricted Share UnitsTSXSEDI:4754058
192,308 sharesRestricted Share UnitsTSXSEDI:4754057
14,781 shares@ US$0.06620.0037% mcap16.4% of flowCommon stockSEC:0001522767-26-000158:1
25 of 152 declarations
关于 MARIMED INC.
MariMed Inc.是一家总部位于马萨诸塞州诺伍德的美国大麻运营商，其公开市场披露和通讯与美国市场相关，并在纳斯达克报道中提及其交易存在；其证券也在OTCQX报价。对于投资者而言，该公司应主要被视为一个多州大麻消费者和品牌平台，而非纯粹的种植故事。MariMed在美国各地开发、拥有和管理获得州许可的从种子到销售的设施，用于医用和成人用大麻的种植、生产和分销。其模式涵盖零售、批发和品牌许可，为其提供了多种收入渠道，并使其能够将品牌影响力扩展到公司自有商店之外。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai)） 历史上，该公司已从一个更广泛的以管理为导向的大麻平台发展成为一个更专注的品牌消费品战略。SEC文件显示，其自有设施、许可证和分销能力逐步建立，反映了其长期致力于创建更具规模的垂直整合业务。MariMed的主要行政办公室位于马萨诸塞州诺伍德Oceana Way 10号。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai)） MariMed的核心业务线包括种植、加工、零售药房运营、批发分销以及通过产品许可实现知识产权货币化。该公司的品牌组合包括Nature’s Heritage、Betty’s Eddies、Kalm Fusion、Bubby’s Baked、Vibations和InHouse。这些品牌涵盖优质花卉、浓缩物、食用产品、水果软糖、咀嚼片、饮料混合物以及其他精确剂量的大麻产品。战略重点是具有重复购买潜力的优质消费品，这是在分散且高度受监管的市场中的一个关键区别。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai)） 在竞争方面，MariMed在一个由大型多州同行主导的行业中，定位为一家专注的利基运营商。它不只在种植规模上竞争，而是旨在通过品牌实力、产品质量和批发渗透率取胜。管理层表示，公司的“扩大品牌”战略旨在增加核心市场的份额，并将分销扩展到高增长州。这种方法对于寻求品牌大麻产品敞口的投资者可能具有吸引力，但它也使公司面临更广泛的美国大麻市场中的价格压力和监管复杂性。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/marimedq22025ex991.htm?utm_source=openai)） 最近的发展对投资案例至关重要。2025年，MariMed报告了收入增长，连续第六年实现正调整后EBITDA，并扩大了其核心市场大部分药房的分销。它还强调了旨在将其品牌影响力扩展到缅因州、宾夕法尼亚州和纽约州的新协议。2026年3月，该公司报告了2025年全年业绩，并表示在战略审查后已退出密苏里州，这表明其资本配置方法更加严谨，并专注于高回报市场。（[nasdaq.com](https://www.nasdaq.com/press-release/marimed-reports-fourth-quarter-and-full-year-2025-earnings-2026-03-11?utm_source=openai)）
